FDA Rejects Atara’s Ebvallo Due to Manufacturing Issues, Not Efficacy or Safety Concerns

Atara Therapeutics, Ebvallo, FDA rejection, manufacturing issues, post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus (EBV), T-cell immunotherapy, Pierre Fabre Laboratories.

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.